Paper24311643
Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.
Karajannis MA and 13 others. Neuro Oncol, 2014. Cited by 93 papers, by iCite.
Cite this record
ConductScience Library. Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas. Papers, record 24311643. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/24311643
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics19
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Antineoplastic Agents | Major topic |
| Neurofibromatosis 2 | Major topic |
| Neuroma, Acoustic | Major topic |
| Sirolimus | Major topic |
| Adolescent | |
| Adult | |
| Child | |
| Disease Progression | |
| Everolimus | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Magnetic Resonance Imaging | |
| Male | |
| Neoplasm Staging | |
| Prognosis | |
| Prospective Studies | |
| Survival Rate | |
| Young Adult |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P30CA016087 | NIH |
Source NIH RePORTER
References33
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 16791048 | The natural history of vestibular schwannoma. | Otol Neurotol | 2006 | https://conductscience.org/library/papers/16791048 | PubMed |
| 2 | 17947729 | Phase I study of everolimus in pediatric patients with refractory solid tumors. | J Clin Oncol | 2007 | https://conductscience.org/library/papers/17947729 | PubMed |
| 3 | 2702835 | Optimal two-stage designs for phase II clinical trials. | Control Clin Trials | 1989 | https://conductscience.org/library/papers/2702835 | PubMed |
| 4 | 19671848 | Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. | Clin Cancer Res | 2009 | https://conductscience.org/library/papers/19671848 | PubMed |
| 5 | 21659604 | The mTOR-regulated phosphoproteome reveals a mechanism of mTORC1-mediated inhibition of growth factor signaling. | Science | 2011 | https://conductscience.org/library/papers/21659604 | PubMed |
| 6 | 22482125 | Merlin: a tumour suppressor with functions at the cell cortex and in the nucleus. | EMBO Rep | 2012 | https://conductscience.org/library/papers/22482125 | PubMed |
| 7 | 713519 | Speech-discrimination scores modeled as a binomial variable. | J Speech Hear Res | 1978 | https://conductscience.org/library/papers/713519 | PubMed |
| 8 | 16371857 | Using audiometric thresholds and word recognition in a treatment study. | Otol Neurotol | 2006 | https://conductscience.org/library/papers/16371857 | PubMed |
| 9 | 19451229 | Loss of the tumor suppressor gene NF2, encoding merlin, constitutively activates integrin-dependent mTORC1 signaling. | Mol Cell Biol | 2009 | https://conductscience.org/library/papers/19451229 | PubMed |
| 10 | 16121974 | Systematic review of the natural history of vestibular schwannoma. | J Neurosurg | 2005 | https://conductscience.org/library/papers/16121974 | PubMed |
| 11 | 19587327 | Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19587327 | PubMed |
| 12 | 21157483 | mTOR: from growth signal integration to cancer, diabetes and ageing. | Nat Rev Mol Cell Biol | 2011 | https://conductscience.org/library/papers/21157483 | PubMed |
| 13 | 15354016 | Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. | Otol Neurotol | 2004 | https://conductscience.org/library/papers/15354016 | PubMed |
| 14 | 19451225 | NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. | Mol Cell Biol | 2009 | https://conductscience.org/library/papers/19451225 | PubMed |
| 15 | 22426462 | Regulation of mTOR complex 2 signaling in neurofibromatosis 2-deficient target cell types. | Mol Cancer Res | 2012 | https://conductscience.org/library/papers/22426462 | PubMed |
| 16 | 22503123 | Long-term natural history of neurofibromatosis Type 2-associated intracranial tumors. | J Neurosurg | 2012 | https://conductscience.org/library/papers/22503123 | PubMed |
| 17 | 19402072 | Targeting mTOR in renal cell carcinoma. | Cancer | 2009 | https://conductscience.org/library/papers/19402072 | PubMed |
| 18 | 21659605 | Phosphoproteomic analysis identifies Grb10 as an mTORC1 substrate that negatively regulates insulin signaling. | Science | 2011 | https://conductscience.org/library/papers/21659605 | PubMed |
| 19 | 7676998 | Spinal tumors in patients with neurofibromatosis type 2: MR imaging study of frequency, multiplicity, and variety. | AJR Am J Roentgenol | 1995 | https://conductscience.org/library/papers/7676998 | PubMed |
| 20 | 21306238 | Everolimus for advanced pancreatic neuroendocrine tumors. | N Engl J Med | 2011 | https://conductscience.org/library/papers/21306238 | PubMed |
Cited by65
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 93 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42958385 | Divergent Schwann cell-immune cell trajectories across vestibular schwannoma subtypes mirror nerve injury-repair programs. | J Neuroinflammation | 2026 | https://conductscience.org/library/papers/42958385 | PubMed |
| 42272870 | T-cell-targeted immunotherapy in neurofibromatosis type 2-related vestibular schwannoma: current evidence and future direction. | Brain Commun | 2026 | https://conductscience.org/library/papers/42272870 | PubMed |
| 42142209 | A review of targeted therapies for NF2-related vestibular schwannoma: molecular pathogenesis, emerging therapeutics, and future clinical horizons. | J Neurooncol | 2026 | https://conductscience.org/library/papers/42142209 | PubMed |
| 41929036 | Quantitative imaging of schwannoma captures heterogeneity and accelerates preclinical testing, revealing distinct impacts of targeted therapies. | bioRxiv | 2026 | https://conductscience.org/library/papers/41929036 | PubMed |
| 41899444 | Targeted Medical Therapy for Vestibular Schwannomas: Evidence, Limits, and Future Directions-A Scoping Review. | Curr Issues Mol Biol | 2026 | https://conductscience.org/library/papers/41899444 | PubMed |
| 41893038 | Targeted and Personalized Therapy for Difficult Benign Brain Tumors: A Review. | J Pers Med | 2026 | https://conductscience.org/library/papers/41893038 | PubMed |
| 41814021 | Emerging systemic treatment strategies for vestibular schwannoma. | J Neurooncol | 2026 | https://conductscience.org/library/papers/41814021 | PubMed |
| 41565922 | Diverse NF2 alterations in cranial schwannomas: a two-case series of germline whole-gene deletion and somatic in-frame deletion. | Brain Tumor Pathol | 2026 | https://conductscience.org/library/papers/41565922 | PubMed |
| 41417846 | Combining Brigatinib with mTOR Inhibition to Effectively Treat NF2-SWN-Associated and Sporadic NF2-Deficient Meningiomas. | Cancer Res Commun | 2026 | https://conductscience.org/library/papers/41417846 | PubMed |
| 40575410 | Phase II study of axitinib in patients with NF2-related schwannomatosis and progressive vestibular schwannomas. | Neurooncol Adv | 2025 | https://conductscience.org/library/papers/40575410 | PubMed |
| 40343504 | Multiplatform molecular analyses reveal two molecular subgroups of NF2-related schwannomatosis vestibular schwannomas with distinct tumour microenvironment and therapeutic vulnerabilities. | Acta Neuropathol | 2025 | https://conductscience.org/library/papers/40343504 | PubMed |
| 39022647 | From bench to bedside: Advancing towards therapeutic treatment of vestibular schwannomas. | Neurooncol Adv | 2024 | https://conductscience.org/library/papers/39022647 | PubMed |
| 38936103 | Paediatric strategy forum for medicinal product development of PI3-K, mTOR, AKT and GSK3β inhibitors in children and adolescents with cancer. | Eur J Cancer | 2024 | https://conductscience.org/library/papers/38936103 | PubMed |
| 38879686 | NF2: An underestimated player in cancer metabolic reprogramming and tumor immunity. | NPJ Precis Oncol | 2024 | https://conductscience.org/library/papers/38879686 | PubMed |
| 38760612 | Gene Therapy for Neurofibromatosis Type 2-Related Schwannomatosis: Recent Progress, Challenges, and Future Directions. | Oncol Ther | 2024 | https://conductscience.org/library/papers/38760612 | PubMed |
| 38372904 | Imaging as an early biomarker to predict sensitivity to everolimus for progressive NF2-related vestibular schwannoma. | J Neurooncol | 2024 | https://conductscience.org/library/papers/38372904 | PubMed |
| 38216553 | Single-cell multi-omic analysis of the vestibular schwannoma ecosystem uncovers a nerve injury-like state. | Nat Commun | 2024 | https://conductscience.org/library/papers/38216553 | PubMed |
| 38058737 | Case report of selumetinib as a novel therapy in a neurofibromatosis type 2-associated ependymoma. | Mol Ther Methods Clin Dev | 2023 | https://conductscience.org/library/papers/38058737 | PubMed |
| 37906356 | Management of Central and Peripheral Nervous System Tumors in Patients with Neurofibromatosis. | Curr Oncol Rep | 2023 | https://conductscience.org/library/papers/37906356 | PubMed |
| 37706198 | A systematic review of targeted therapy for vestibular schwannoma in patients with NF2-related schwannomatosis. | Neurooncol Adv | 2023 | https://conductscience.org/library/papers/37706198 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| MTOR | 2475 | PubTator's text mining | https://conductscience.org/library/genes/2475 | NCBI Gene |
| NF2 | 4771 | PubTator's text mining | https://conductscience.org/library/genes/4771 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/24311643
GET https://conductscience.org/api/papers/v1/24311643/references?page=2